{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:26:27Z","timestamp":1791260787498,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Resistance to paclitaxel-based chemotherapy represents a major clinic challenge in triple-negative breast cancer (TNBC). Insights on the regulation genes of chemoresistance and underlying mechanisms in TNBC are waiting for in-depth investigation to address the current treatment bottlenecks. In this study, we identified that ubiquitin carboxyl terminal hydrolase-L1 (UCH-L1) was preferentially overexpressed in TNBC and correlated with worse prognosis as well as poor response to chemotherapy. Upregulation of UCH-L1 attenuated the inhibitory effect of paclitaxel on tumor cells through modulating the aerobic glycolysis, while knockdown of UCH-L1 increased the responsiveness of TNBC cells to the drug both in vitro and in vivo. Coimmunoprecipitation results revealed that the N terminal of UCH-L1 interacts with the C-terminal domain of pyruvate kinase M2 (PKM2). UCH-L1 stabilized PKM2 via removing K48-linked polyubiquitination of PKM2 protein at K498, and thereby promoting glycolysis. Moreover, the expression levels of UCH-L1 and PKM2 were elevated in paclitaxel-resistant TNBC cells, and inhibition of UCH-L1\/PKM2 axis-mediated glycolysis markedly sensitized the cells to paclitaxel treatment. Meanwhile, high expression of PKM2 was associated with shorter overall survival in TNBC patients who received chemotherapy. Clinically, PKM2 expression is positively correlated with the expression of UCH-L1 in TNBC tissues. In conclusion, our study reveals that high-expressed UCH-L1 was one of the biomarkers predicting and determining chemosensitivities of TNBC by advancing the cleavage of K48-linked polyubiquitin chains from PKM2 and enhancing glycolysis, and suggests that targeting UCH-L1\/PKM2 axis holds great promise for reversing chemoresistance.<\/jats:p>","DOI":"10.1038\/s41419-026-08521-7","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:18:18Z","timestamp":1771993098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Deubiquitinase UCH-L1 confers paclitaxel resistance via stabilizing PKM2 to promote glycolysis in triple-negative breast cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3091-2919","authenticated-orcid":false,"given":"Xisha","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingcai","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4593-4897","authenticated-orcid":false,"given":"Jing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0049-128X","authenticated-orcid":false,"given":"Taolan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyu","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"8521_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"8521_CR2","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","volume":"186","author":"E Nolan","year":"2023","unstructured":"Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023;186:1708\u201328.","journal-title":"Cell"},{"key":"8521_CR3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176\u201398.","journal-title":"Cancer Discov"},{"key":"8521_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.19.00368","volume":"38","author":"P Schmid","year":"2020","unstructured":"Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial. J Clin Oncol. 2020;38:423\u201333.","journal-title":"J Clin Oncol"},{"key":"8521_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2020.10.016","volume":"497","author":"X Bai","year":"2021","unstructured":"Bai X, Ni J, Beretov J, Graham P, Li Y. Triple-negative breast cancer therapeutic resistance: Where is the Achilles\u2019 heel? Cancer Lett. 2021;497:100\u201311.","journal-title":"Cancer Lett"},{"key":"8521_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34:355\u201377.","journal-title":"Cell Metab"},{"key":"8521_CR7","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","volume":"21","author":"I Mart\u00ednez-Reyes","year":"2021","unstructured":"Mart\u00ednez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21:669\u201380.","journal-title":"Nat Rev Cancer"},{"key":"8521_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.apsb.2021.09.019","volume":"12","author":"D Du","year":"2022","unstructured":"Du D, Liu C, Qin M, Zhang X, Xi T, Yuan S, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sin B. 2022;12:558\u201380.","journal-title":"Acta Pharm Sin B"},{"key":"8521_CR9","doi-asserted-by":"crossref","unstructured":"Chelakkot C, Chelakkot VS, Shin Y, Song K. Modulating glycolysis to improve cancer therapy. Int J Mol Sci. 2023;24.","DOI":"10.3390\/ijms24032606"},{"key":"8521_CR10","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.semcancer.2022.09.007","volume":"86","author":"S Paul","year":"2022","unstructured":"Paul S, Ghosh S, Kumar S. Tumor glycolysis, an essential sweet tooth of tumor cells. Semin Cancer Biol. 2022;86:1216\u201330.","journal-title":"Semin Cancer Biol"},{"key":"8521_CR11","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.15252\/embr.201643300","volume":"17","author":"TL Dayton","year":"2016","unstructured":"Dayton TL, Jacks T, Vander Heiden MG. PKM2, cancer metabolism, and the road ahead. EMBO Rep. 2016;17:1721\u201330.","journal-title":"EMBO Rep"},{"key":"8521_CR12","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/ncb2629","volume":"14","author":"W Yang","year":"2012","unstructured":"Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F, et al. ERK1\/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol. 2012;14:1295\u2013304.","journal-title":"Nat Cell Biol"},{"key":"8521_CR13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.molcel.2013.09.004","volume":"52","author":"L Lv","year":"2013","unstructured":"Lv L, Xu YP, Zhao D, Li FL, Wang W, Sasaki N, et al. Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol Cell. 2013;52:340\u201352.","journal-title":"Mol Cell"},{"key":"8521_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1271-9","volume":"10","author":"H Qi","year":"2019","unstructured":"Qi H, Ning X, Yu C, Ji X, Jin Y, McNutt MA, et al. Succinylation-dependent mitochondrial translocation of PKM2 promotes cell survival in response to nutritional stress. Cell Death Dis. 2019;10:170.","journal-title":"Cell Death Dis"},{"key":"8521_CR15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41388-019-0975-3","volume":"39","author":"JP Singh","year":"2020","unstructured":"Singh JP, Qian K, Lee JS, Zhou J, Han X, Zhang B, et al. O-GlcNAcase targets pyruvate kinase M2 to regulate tumor growth. Oncogene. 2020;39:560\u201373.","journal-title":"Oncogene"},{"key":"8521_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122719","volume":"349","author":"P Singla","year":"2024","unstructured":"Singla P, Jain A. Deciphering the complex landscape of post-translational modifications on PKM2: Implications in head and neck cancer pathogenesis. Life Sci. 2024;349:122719.","journal-title":"Life Sci"},{"key":"8521_CR17","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1021\/bi972274d","volume":"37","author":"CN Larsen","year":"1998","unstructured":"Larsen CN, Krantz BA, Wilkinson KD. Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry. 1998;37:3358\u201368.","journal-title":"Biochemistry"},{"key":"8521_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.neuint.2007.05.007","volume":"51","author":"R Setsuie","year":"2007","unstructured":"Setsuie R, Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int. 2007;51:105\u201311.","journal-title":"Neurochem Int"},{"key":"8521_CR19","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1182\/blood-2018-05-848515","volume":"132","author":"S Hussain","year":"2018","unstructured":"Hussain S, Bedekovics T, Liu Q, Hu W, Jeon H, Johnson SH, et al. UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice. Blood. 2018;132:2564\u201374.","journal-title":"Blood"},{"key":"8521_CR20","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1158\/1078-0432.CCR-19-1373","volume":"26","author":"S Liu","year":"2020","unstructured":"Liu S, Gonz\u00e1lez-Prieto R, Zhang M, Geurink PP, Kooij R, Iyengar PV, et al. Deubiquitinase activity profiling identifies UCHL1 as a candidate oncoprotein that promotes TGF\u03b2-induced breast cancer metastasis. Clin Cancer Res. 2020;26:1460\u201373.","journal-title":"Clin Cancer Res"},{"key":"8521_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/onc.2008.364","volume":"28","author":"HJ Kim","year":"2009","unstructured":"Kim HJ, Kim YM, Lim S, Nam YK, Jeong J, Kim HJ, et al. Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene. 2009;28:117\u201327.","journal-title":"Oncogene"},{"key":"8521_CR22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.canlet.2011.01.006","volume":"302","author":"MJ Jang","year":"2011","unstructured":"Jang MJ, Baek SH, Kim JH. UCH-L1 promotes cancer metastasis in prostate cancer cells through EMT induction. Cancer Lett. 2011;302:128\u201335.","journal-title":"Cancer Lett"},{"key":"8521_CR23","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/jcb.26232","volume":"119","author":"Y Luo","year":"2018","unstructured":"Luo Y, He J, Yang C, Orange M, Ren X, Blair N, et al. UCH-L1 promotes invasion of breast cancer cells through activating Akt signaling pathway. J Cell Biochem. 2018;119:691\u2013700.","journal-title":"J Cell Biochem"},{"key":"8521_CR24","first-page":"192","volume":"8","author":"T Yamazaki","year":"2002","unstructured":"Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y, et al. PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res. 2002;8:192\u20135.","journal-title":"Clin Cancer Res"},{"key":"8521_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41416-021-01516-5","volume":"126","author":"M Mondal","year":"2022","unstructured":"Mondal M, Conole D, Nautiyal J, Tate EW. UCHL1 as a novel target in breast cancer: emerging insights from cell and chemical biology. Br J Cancer. 2022;126:24\u201333.","journal-title":"Br J Cancer"},{"key":"8521_CR26","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.7150\/thno.39814","volume":"10","author":"XS Chen","year":"2020","unstructured":"Chen XS, Wang KS, Guo W, Li LY, Yu P, Sun XY, et al. UCH-L1-mediated down-regulation of estrogen receptor \u03b1 contributes to insensitivity to endocrine therapy for breast cancer. Theranostics. 2020;10:1833\u201348.","journal-title":"Theranostics"},{"key":"8521_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cmet.2018.04.022","volume":"28","author":"W Li","year":"2018","unstructured":"Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, et al. Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer. Cell Metab. 2018;28:87\u2013103.e6.","journal-title":"Cell Metab"},{"key":"8521_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102588","volume":"298","author":"Q Guo","year":"2022","unstructured":"Guo Q, Qiu Y, Liu Y, He Y, Zhang G, Du Y, et al. Cell adhesion molecule CD44v10 promotes stem-like properties in triple-negative breast cancer cells via glucose transporter GLUT1-mediated glycolysis. J Biol Chem. 2022;298:102588.","journal-title":"J Biol Chem"},{"key":"8521_CR29","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","volume":"173","author":"C Kim","year":"2018","unstructured":"Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell. 2018;173:879\u201393.e13.","journal-title":"Cell"},{"key":"8521_CR30","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.molcel.2015.09.025","volume":"60","author":"ED Montal","year":"2015","unstructured":"Montal ED, Dewi R, Bhalla K, Ou L, Hwang BJ, Ropell AE, et al. PEPCK Coordinates the regulation of central carbon metabolism to promote cancer cell growth. Mol Cell. 2015;60:571\u201383.","journal-title":"Mol Cell"},{"key":"8521_CR31","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.cmet.2024.07.011","volume":"36","author":"G Li","year":"2024","unstructured":"Li G, Wang D, Zhai Y, Pan C, Zhang J, Wang C, et al. Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma. Cell Metab. 2024;36:1696\u2013710.e10.","journal-title":"Cell Metab"},{"key":"8521_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216896","volume":"591","author":"E Dai","year":"2024","unstructured":"Dai E, Wang W, Li Y, Ye D, Li Y. Lactate and lactylation: behind the development of tumors. Cancer Lett. 2024;591:216896.","journal-title":"Cancer Lett"},{"key":"8521_CR33","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41586-024-07620-9","volume":"631","author":"H Chen","year":"2024","unstructured":"Chen H, Li Y, Li H, Chen X, Fu H, Mao D, et al. NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance. Nature. 2024;631:663\u20139.","journal-title":"Nature"},{"key":"8521_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189089","volume":"1879","author":"S Upadhyay","year":"2024","unstructured":"Upadhyay S, Khan S, Hassan MI. Exploring the diverse role of pyruvate kinase M2 in cancer: navigating beyond glycolysis and the Warburg effect. Biochim Biophys Acta Rev Cancer. 2024;1879:189089.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8521_CR35","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.freeradbiomed.2019.08.007","volume":"143","author":"M Alquraishi","year":"2019","unstructured":"Alquraishi M, Puckett DL, Alani DS, Humidat AS, Frankel VD, Donohoe DR, et al. Pyruvate kinase M2: a simple molecule with complex functions. Free Radic Biol Med. 2019;143:176\u201392.","journal-title":"Free Radic Biol Med"},{"key":"8521_CR36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13578-019-0317-8","volume":"9","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Deng X, Liu Y, Liu Y, Sun L, Chen F. PKM2, function and expression and regulation. Cell Biosci. 2019;9:52.","journal-title":"Cell Biosci"},{"key":"8521_CR37","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.cell.2011.03.054","volume":"145","author":"W Luo","year":"2011","unstructured":"Luo W, Hu H, Chang R, Zhong J, Knabel M, O\u2019Meally R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 2011;145:732\u201344.","journal-title":"Cell"},{"key":"8521_CR38","doi-asserted-by":"publisher","first-page":"13732","DOI":"10.1073\/pnas.1704145115","volume":"114","author":"Y Wang","year":"2017","unstructured":"Wang Y, Liu J, Jin X, Zhang D, Li D, Hao F, et al. O-GlcNAcylation destabilizes the active tetrameric PKM2 to promote the Warburg effect. Proc Natl Acad Sci USA. 2017;114:13732\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8521_CR39","doi-asserted-by":"publisher","first-page":"10307","DOI":"10.1074\/jbc.M115.703066","volume":"291","author":"K Liu","year":"2016","unstructured":"Liu K, Li F, Han H, Chen Y, Mao Z, Luo J, et al. Parkin regulates the activity of pyruvate kinase M2. J Biol Chem. 2016;291:10307\u201317.","journal-title":"J Biol Chem"},{"key":"8521_CR40","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1038\/onc.2017.31","volume":"36","author":"Y Shang","year":"2017","unstructured":"Shang Y, He J, Wang Y, Feng Q, Zhang Y, Guo J, et al. CHIP\/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma. Oncogene. 2017;36:4191\u2013200.","journal-title":"Oncogene"},{"key":"8521_CR41","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8450606","volume":"2020","author":"P Yuan","year":"2020","unstructured":"Yuan P, Zhou Y, Wang R, Chen S, Wang Q, Xu Z, et al. TRIM58 interacts with pyruvate kinase M2 to inhibit tumorigenicity in human osteosarcoma cells. Biomed Res Int. 2020;2020:8450606.","journal-title":"Biomed Res Int"},{"key":"8521_CR42","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.3892\/ijo.2015.2901","volume":"46","author":"SR Kim","year":"2015","unstructured":"Kim SR, Kim JO, Lim KH, Yun JH, Han I, Baek KH. Regulation of pyruvate kinase isozyme M2 is mediated by the ubiquitin-specific protease 20. Int J Oncol. 2015;46:2116\u201324.","journal-title":"Int J Oncol"},{"key":"8521_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116323","volume":"173","author":"KQ Li","year":"2024","unstructured":"Li KQ, Bai X, Ke AT, Ding SQ, Zhang CD, Dai DQ. Ubiquitin-specific proteases: from biological functions to potential therapeutic applications in gastric cancer. Biomed Pharmacother. 2024;173:116323.","journal-title":"Biomed Pharmacother"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08521-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08521-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08521-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T12:02:34Z","timestamp":1773489754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08521-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8521"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08521-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study complies with all relevant ethical regulations and was approved by the Medical Ethics Committee of the First Affiliated Hospital of the University of South China. Written informed consent was provided by all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"261"}}